Clinical

Dataset Information

0

The impact of bacterial binding dressings following colorectal surgery on surgical wound complications in an adult population.


ABSTRACT: Interventions: Trial participants will be allocated to either the intervention or control group. There is currently only one DACC dressing (Leukomed Sorbact) available in the wound care dressing. The intervention group will receive the DACC containing dressings following surgery (Leukokmed Sorbact). The DACC dressing is a cover dressing applied over the incision site The control group will receive a dressing that does not contain DACC and has the same dressing properties without the interventional dressing characteristics. Participants allocated to the control group will receive a non DACC dressing. The wear time for both groups will be 14 days, unless otherwise clinical indicated for a dressing change and assessment by the lead PI. Dressing application and wear time is to be conducted according to the manufacturer specifications. Dressings will be applied as per standard of post operative care. Dressings will be visually checked daily by the study lead wound care clinician. Primary outcome(s): The primary outcome will be determined by clinical assessment and diagnosis as well as patient reported outcome. Post discharge surveillance using telemedicine and a phone call at 3o days will be conducted on all trial participants. The primary outcome measurement is defined as the occurrence of surgical site infection as per Centres of Disease Control definition and coding ICD-11 T81.49. [Day 30 postoperative ];The primary outcome measurement is defined as the occurrence of surgical wound dehiscence as defined by World Union of Wound Healing Societies definition and coding ICD 11: T81.3. Post discharge surveillance will be conducted using telemedicine and a phone call at 30 days after surgery. [Day 30 postoperative. ] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Infection-studies Of Infection And Infectious Agents,Skin-other Skin Conditions,Cancer-bowel-small Bowel (duodenum And Ileum),Colorectal Surgery,Cancer-bowel-back Passage (rectum) Or Large Bowel (colon),Wound Healing

PROVIDER: 22999 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-12-26 | GSE269483 | GEO
2024-03-08 | GSE260761 | GEO
| PRJNA1047734 | ENA
2024-07-13 | GSE264681 | GEO
2023-08-22 | PXD025748 | panorama
2022-08-08 | E-MTAB-11799 | biostudies-arrayexpress
2023-08-23 | GSE233863 | GEO
2024-07-30 | GSE271487 | GEO
2023-02-18 | PXD040252 |
2008-06-15 | E-GEOD-7103 | biostudies-arrayexpress